Abiomed, Inc.

ABMD Details

Abiomed, Inc. (NASDAQ: ABMD) provides medical devices that provide circulatory support and oxygenation. ABMD develops, manufactures, and markets products designed to enable the heart to rest, heal, and recover by improving blood flow to the coronary arteries and end-organs and temporarily performing the heart's pumping function. Its product pipeline consists of Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices that have cured thousands of patients globally.

Progress Towards Regulatory Approval: On August 18, 2021, ABMD announced that the US Food and Drug Administration (FDA) had granted breakthrough device designation to its Impella heart pump, which is the world's smallest heart pump measuring 3mm in diameter which expands in the heart to support the heart's pumping function, providing a flow rate of more than 3.5 L/min. This designation by the FDA will accelerate the Impella ECP's regulatory review process and pre-market approval application. 

Treating Coronary Disorders Through Innovation: On June 29, 2021, FDA granted pre-market approval to ABMD's Impella RP, its latest right heart pump, as a safe and effective to treat acute right heart failure for up to 14 days.

Acquisition of preCARDIA: On June 01, 2021, ABMD acquired the remaining stake in preCARDIA, developer of a proprietary catheter and controller, for USD 82.8 million. The acquisition will complement ABMD's product portfolio by enhancing treatment options for acute decompensated heart failure (ADHF).

Q1FY22 Results:  The company reported YoY growth of 53.22% in revenue to USD 252.59 million in Q1FY22 (ended June 30, 2021) compared to USD 164.85 million in Q1FY21. Product revenue, which represented 95.60% of the total revenue in Q1FY22, increased 55.37% YoY, driven by higher utilization of Impella heart pump in the US, whereas the Service and other revenue registered an improvement of 17.79% YoY. ABMD reported a net loss of USD 26.53 million in Q1FY22 vs. a net income of USD 44.59 million in Q1FY21. As of June 30, 2021, the company stood with cash and cash equivalents (including short-term investments) of USD 523.03 million and no outstanding debt.

Key Risks: ABMD generates most of its revenue from Impella products and services. Therefore, any decline in endorsement by physicians and the readiness of patients to purchase the products or disruption in manufacturing and quality issues of Impella devices could hurt the company's financials. In addition, about 18% of ABMD's revenues were in currencies other than USD in Q1FY22, thus exposing it to exchange rate fluctuations.

Outlook: In FY22, ABMD expects to generate total revenue in the range of USD 1.03 – 1.05 billion, thus realizing YoY growth of 22% – 24%, along with a non-GAAP operating margin to the tune of 24% - 26%.

Valuation Methodology: Price/Earnings Per Share-Based Relative Valuation

 (Analysis by Kalkine Group)

• % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

ABMD Daily Technical Chart (Source: REFINITIV)

Stock Recommendation: ABMD's stock price has increased 25.98% in the past three months and is currently trading close to the higher-end of its 52-week range of USD 242.73 to USD 387.40. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is at 69.83. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 304.83. Considering the uptick in the stock price, we believe the current price adequately reflects the business fundamentals and recommend a "Sell" rating on the stock at the current price of USD 357.63, up 1.65% as of August 24, 2021, 12:39 PM ET.

* All forecasted figures and Industry Information have been taken from REFINITIV.

*The reference data in this report has been partly sourced from REFINITIV.    

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.